NCT04191395 Evolution and Treatments of Chronic Inflammatory Systemic Diseases
| NCT ID | NCT04191395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Condition | Inflammatory Bowel Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2019-12-11 |
| Primary Completion | 2029-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2019-12-11 with a primary completion date of 2029-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease \[MC\] and ulcerative colitis \[RCH\]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis \[RA\] and spondyloarthritis \[SpA\] including psoriatic arthritis \[PsA\]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.
Eligibility Criteria
Inclusion Criteria: * Patients treated for IBD (MC, UC or indeterminate colitis) in the gastroenterology department of Besançon University Hospital * Subject meeting the clinical, morphological and histological diagnostic criteria for MC, UC or indeterminate colitis or * Patients treated for chronic inflammatory rheumatism (RA, SpA, PsA) in the rheumatology department of the University Hospital of Besançon Subject meeting the ACR 2010 classification criteria of RA or modified New York criteria of Ankylosing spondylitis or ASAS criteria of axial or peripheral SpA or CASPAR criteria of PsA or * Patients treated for chronic inflammatory skin disease (Psoriasis, Verneuil's disease) in the dermatology department of the University Hospital of Besançon Exclusion Criteria: * Opposition of the patient * Patients in emergency situation, persons deprived of their liberty, protected minors or adults.
Contact & Investigator
Clément Prati, Prof.
PRINCIPAL INVESTIGATOR
CHU Besançon
Frequently Asked Questions
Who can join the NCT04191395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Bowel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04191395 currently recruiting?
Yes, NCT04191395 is actively recruiting participants. Contact the research team at cvauchy@chu-besancon.fr for enrollment information.
Where is the NCT04191395 trial being conducted?
This trial is being conducted at Besançon, France.
Who is sponsoring the NCT04191395 clinical trial?
NCT04191395 is sponsored by Centre Hospitalier Universitaire de Besancon. The principal investigator is Clément Prati, Prof. at CHU Besançon. The trial plans to enroll 3,000 participants.